Tailored Axillary Surgery With or Without Axillary Lymph Node Dissection Followed by Radiotherapy in Patients With Clinically Node-positive Breast Cancer (TAXIS) (TAXIS)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03513614 |
|
Recruitment Status :
Recruiting
First Posted : May 1, 2018
Last Update Posted : December 22, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
RATIONALE: The use of tailored axillary dissection as a tailored procedure will avoid surgical overtreatment by selectively removing the lymph nodes that are affected by the cancer, thereby sparing many women the unnecessary complications of a radical surgery, providing a better quality of life while keeping the same efficacy.
PURPOSE: The phase III trial is evaluating the optimal treatment for breast cancer patients in terms of surgery and radiotherapy.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Node-positive Breast Cancer | Procedure: Tailored axillary surgery - both Arms Radiation: Radiotherapy - Arm A Radiation: Radiotherapy - Arm B | Not Applicable |
The removal of all lymph nodes in the armpit through conventional axillary dissection has been standard care for all patients with breast cancer for almost a century. In the nineties, the sentinel lymph node procedure, which involves the selective removal of the first few affected lymph nodes, was introduced in clinical practice. Today, conventional axillary dissection is still performed on many women with breast cancer that has spread to the nodes. It is the cause for relevant morbidity in the form of lymphedema, impairment of shoulder mobility, sensation disorders and chronic pain in as much as one third of all women undergoing the procedure.
The TAXIS trial will evaluate the optimal treatment for breast cancer patients in terms of surgery and radiotherapy. In particular, it will investigate the value of tailored axillary surgery (TAS), a new technique that aims at selectively removing the positive lymph nodes. TAS combines the removal of palpably suspicious nodes with the sentinel procedure. TAS is a promising procedure that may significantly decrease morbidity in breast cancer patients by avoiding surgical overtreatment.
This trial has the potential to establish a new worldwide treatment standard with hopefully less side effects and a better quality of life, while keeping the same efficacy as provided by radical surgery.
The main objective of the trial is to show that TAS and axillary radiotherapy (RT) is non-inferior to ALND in terms of disease-free survival of node positive breast cancer patients at high risk of recurrence in the era of effective systemic therapy and extended regional nodal irradiation.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 1500 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Tailored Axillary Surgery With or Without Axillary Lymph Node Dissection Followed by Radiotherapy in Patients With Clinically Node-positive Breast Cancer (TAXIS). A Multicenter Randomized Phase III Trial (OPBC-03/ SAKK 23/16 /IBCSG 57-18 / ABCSG-53 / GBG-101) |
| Actual Study Start Date : | August 7, 2018 |
| Estimated Primary Completion Date : | December 2029 |
| Estimated Study Completion Date : | December 2036 |
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: ALND
Tailored axillary surgery followed by axillary lymph node dissection (ALND) and regional nodal irradiation excluding the dissected axilla.
|
Procedure: Tailored axillary surgery - both Arms
Axillary lymph node dissection - Arm A Radiation: Radiotherapy - Arm A Regional nodal irradiation excluding the dissected axilla - Arm A |
|
Active Comparator: No ALND
Tailored axillary surgery followed by regional nodal irradiation including the full axilla.
|
Procedure: Tailored axillary surgery - both Arms
Axillary lymph node dissection - Arm A Radiation: Radiotherapy - Arm B Regional nodal irradiation including the full axilla - Arm B |
- Disease-free survival (DFS) [ Time Frame: at the occurrence of the event or latest 20 years after randomization of the last patient ]
The primary endpoint of this trial is DFS, defined as time from randomization until one of the following events, whichever comes first:
- Local recurrence, regional recurrence, distant recurrence
- Second breast cancer
- Death from any cause Patients not experiencing an event will be censored at the date of the last available assessment.
- Overall survival (OS) [ Time Frame: at the occurrence of the event or latest 20 years after randomization of the last patient ]OS will be calculated from randomization until death from any cause. Patients not experiencing an event will be censored at the last date they were known to be alive.
- Breast cancer-specific survival (BCSS) [ Time Frame: at the occurrence of the event or latest 20 years after randomization of the last patient ]BCSS will be calculated from randomization until death from breast cancer. Patients not experiencing an event will be censored at the last date they were known to be alive.
- Time to local recurrence (TTLR) [ Time Frame: at the occurrence of the event or latest 20 years after randomization of the last patient ]TTLR will be calculated from randomization until local recurrence or death from breast cancer. Patients not experiencing an event or patients who died due to other reasons before experiencing an event will be censored at the date of the last available assessment.
- Time to distant recurrence (TTDR) [ Time Frame: at the occurrence of the event or latest 20 years after randomization of the last patient ]TTDR will be calculated from randomization until distant recurrence or death from breast cancer. Patients not experiencing an event or patients who died due to other reasons before experiencing an event will be censored at the date of the last available assessment.
- Physician reported morbidity outcomes (Lymphedema) [ Time Frame: at baseline, at week 1 and 4 after surgery, before the beginning of radiotherapy. During follow-up: 9 and 12 months after randomization then every 6 months up to 3 years, then every year up to 20 years after randomization of the last patient. ]
- Physician reported morbidity outcomes (Decreased range of shoulder motion) [ Time Frame: at baseline, at week 1 and 4 after surgery. During follow-up: 9 and 12 months after randomization then every 6 months up to 3 years, then every year up to 10 years after randomization of the last patient. ]
- Adverse events according to NCI CTCAE v4.03 [ Time Frame: from date of patient consent and up to 20 years after randomization of the last patient ]Clipping-related AEs and specific AEs related to the surgical procedure and radiotherapy will be assessed according to NCI CTCAE v4.03.
- Late radiotherapy-related adverse events [ Time Frame: from date of patient consent and up to 20 years after randomization of the last patient ]Late adverse events related to the radiotherapy will be assessed according to the Late Effects in Normal Tissues-Subjective, Objective, Management and Analytic (LENT-SOMA) scale
- Surgical site infections (SSI) [ Time Frame: from date of patient consent and up to 20 years after randomization of the last patient ]SSIs will be assessed according to the Centers for Disease Control and Prevention Surgical Site Infection Classification System.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Inclusion criteria at pre-registration:
- Written informed consent according to ICH/GCP regulations prior to any trial specific procedures.
- Breast cancer, node positive detected by palpation or imaging (with or without planned neoadjuvant treatment)
- Female or male aged ≥ 18 years
- Ability to complete the Quality of Life questionnaires
Inclusion criteria at registration:
-
Node-positive breast cancer (histologically or cytologically proven both in primary tumor and in lymph node) AJCC/UICC [42] stage II-III (all molecular subtypes allowed):
- Node-positivity detected by imaging (iN+) and confirmed by pathology
- Node-positivity detected by palpation (cN1-2) and confirmed by pathology Note: occult breast cancer is allowed, if biopsy-proven axillary lymphatic metastasis is present
-
Eligible for primary ALND or sentinel lymph node (SLN) procedure with frozen section and either:
- Newly diagnosed
- Isolated in-breast recurrence or second ipsilateral breast cancer after previous breast conserving surgery and sentinel procedure and at least 3 years disease free and no prior axillary dissection or axillary RT
- Most suspicious axillary lymph node clipped
- Baseline Quality of Life questionnaire has been completed
- WHO performance status 0-2
- Adequate condition for general anesthesia and breast cancer surgery
- Women with child-bearing potential are using effective contraception, are not pregnant or lactating and agree not to become pregnant during trial treatment and thereafter during the time recommended by the guidelines for adjuvant systemic therapies. A negative pregnancy test before inclusion into the trial is required for all women with child-bearing potential.
- Men agree not to father a child during trial treatment and thereafter during 6 months.
Inclusion criteria at randomization (intraoperatively)
-
Node-positive breast cancer (histologically or cytologically proven both in primary tumor and in lymph node) AJCC/UICC stage II-III (all molecular subtypes allowed):
- Node-positivity initially detected by imaging and non-palpable and residual disease confirmed by pathology** (including residual ITCs) in SLN or non SLN in case of prior neoadjuvant treatment
-
Node-positivity initially palpable and residual disease confirmed by pathology** (including residual ITCs) in case of prior neoadjuvant treatment
- Note: patients with ypN0(i+) can be included (the AJCC stage II-III refers to the stage before neoadjuvant treatment) **Note: If the fine needle aspiration or core biopsy of the clipped node after neoadjuvant treatment unequivocally shows cancer, repeated confirmation of residual disease by intraoperative frozen section is not mandatory
Exclusion Criteria:
Exclusion criteria at pre-registration:
Any potential patient who meets any of the following criteria has to be excluded from entering the trial.
- Stage IV breast cancer
- Clinical N3c breast cancer (clinical N3a and clinical N3b are allowed)
- Clinical N2b breast cancer (clinical N2a is allowed)
- Contralateral breast cancer within 3 years Note: Contralateral Ductal Carcinoma In Situ (DCIS) is allowed if prior treatment does not interfere with or compromise the trial treatment
- Prior axillary surgery (except prior sentinel node procedure in case of in- breast recurrence)
- Prior regional radiotherapy
- History of hematologic or primary solid tumor malignancy, unless in remission for at least 3 years from pre-registration with the exception of adequately treated cervical carcinoma in situ or localized non-melanoma skin cancer.
- Treatment with any experimental drug within 30 days of pre-registration
- Any other serious underlying medical, psychiatric, psychological, familial or geographical condition, which in the judgment of the investigator may interfere with the planned staging, treatment and follow-up, affect patient compliance or place the patient at high risk from treatment-related complications.
Exclusion criteria at randomization (intraoperatively):
Any potential patient who meets any of the following criteria has to be excluded from the trial.
- Absence of clip in the specimen radiography
- Palpable disease left behind in the axilla after Tailored Axillary Surgery (TAS)
- No SLN identified in the axilla
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03513614
| Contact: Walter P. Weber, Prof. | +41 61 328 61 49 | walter.weber@usb.ch | |
| Contact: Alexandra Schulz | +41 61 328 5401 | alexandra.schulz@usb.ch |
Show 47 study locations
| Study Chair: | Walter P. Weber, Prof. | University Hospital, Basel, Switzerland |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | University Hospital, Basel, Switzerland |
| ClinicalTrials.gov Identifier: | NCT03513614 |
| Other Study ID Numbers: |
2018-00838; ch20Weber2 2018-000372-14 ( EudraCT Number ) |
| First Posted: | May 1, 2018 Key Record Dates |
| Last Update Posted: | December 22, 2022 |
| Last Verified: | December 2022 |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Tailored Axillary Surgery TAXIS Breast Cancer node-positive breast cancer |
phase III trial IBCSG 57-18 ABCSG |
|
Breast Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases |